Reducing Risk of Transplantation for People with IgA Nephropathy: What Managed Care Pharmacists Can Do to Help Optimize Treatment

Pricing: Free for Members and Non-Members

This activity is jointly provided by the Academy of Managed Care Pharmacy, Global Education Group, and PlatformQ Health Education, LLC, in collaboration with Kidney Disease: Improving Global Outcomes (KDIGO).

 

This course is hosted on an external platform. Click the course title below to register and access the course:

Reducing Risk of Transplantation for People with IgA Nephropathy: What Managed Care Pharmacists Can Do to Optimize Treatment

Course Description

Because it is “silent” or asymptomatic, patients with immunoglobulin-A nephropathy (IgAN) often experience diagnostic delay. A common cause of kidney failure that can necessitate kidney transplantation, IgAN can also recur after transplantation, leading to allograft failure. People with IgAN suffer from heightened pain and fatigue, as well as negative impacts on quality of life (QoL) and mental health.

Several targeted treatment options with improved efficacy and safety compared to current care have recently been or are being developed. These therapies are poised to address unmet needs and reduce risk of transplantation.

Join an expert nephrologist and pharmacist to discuss these new and emerging treatment options, up-to-date evidence on their safety and efficacy, and recommendations from practice guidelines. Managed care pharmacists will be prepared to enhance access to these beneficial treatments and include them in medication-management programs for appropriate patients with IgAN.


 

Target Audience

Pharmacists who practice in managed care settings.

Learning Objectives

At the conclusion of this activity, participants should be able to demonstrate improved ability to:

  1. Describe the burden of IgAN and the inability of current treatment approaches to reduce risk of transplantation
  2. Summarize data supporting the efficacy and safety of dual inhibition of RAS and endothelin-1 to reduce proteinuria and slow kidney-function decline in those with IgAN more than RAS inhibition alone does
  3. Recognize the place of dual inhibitors of RAS and endothelin-1 to treat IgAN, delay risk of transplantation, and reduce overall cost of care
Course summary
Available credit: 
  • 1.00 ACPE
    ACPE The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Course opens: 
05/15/2023
Course expires: 
12/31/2024
Cost:
$0.00

 

 

 

Faculty

Rosanna Coppo, MD, FERA
Nephrologist
Fon​​​​​​​dazion​​​​​​​e Ricerca Molinette​​​​​​​
Regina Ma​​​​​​​rgherita Hospital​​​​​​​
​​​​​​​​​​​​​​​​​​​​

Michelle M. Richardson, PharmD
Special and Scientific Staff​​​​​​​
William B. Schwartz Division of Nephrology
Tufts Medical Center
Assistant Professor of Medicine​​​​​​​
Tufts University School of Medicine

Available Credit

  • 1.00 ACPE
    ACPE The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Price

Cost:
$0.00
Please login or register to take this course.

This course is hosted on an external platform. Click the course title below to register and access the course:

Reducing Risk of Transplantation for People with IgA Nephropathy: What Managed Care Pharmacists Can Do to Optimize Treatment